Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis
- PMID: 2504171
- DOI: 10.1002/anr.1780320805
Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis
Abstract
One hundred five patients were enrolled in a 12-week, randomized, prospective, double-blind, placebo-controlled trial of recombinant human gamma-interferon (rHu gamma-IFN) for the treatment of rheumatoid arthritis. Fifty-four patients received rHu gamma-IFN and 51 received placebo. Forty-two patients in each group completed the 12-week trial. Some clinical improvement occurred in both groups of patients. Although the improvement with rHu gamma-IFN was greater than that with placebo, the differences were generally not statistically significant.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
